Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2000

View Archived Issues

deCODE identifies schizophrenia gene

American Home Products and Aventis renegotiate agreement

Update on Pharmacia's ocular medications

Prilosec receives positive recommendation for OTC status

Pharmacokinetics, pharmacodynamics and safety of i.v. RGD-891 studied in healthy volunteers

PSC-833 produces marked but incomplete reversal of MDR in the presence of human serum

Design of AMPA-selective compounds with a triazoloquinoxaline-2-carboxylate framework

SRL-172 has positive effects on response rate, survival and quality of life in NSCLC

CS-834: oral absorption kinetics in rats reported at recent scientific meeting

HIV protease inhibitor Agenerase approved in E.U.

Serono to develop Axonyx's amyloid- and prion-inhibitory peptides

Once-weekly Fosamax approved by FDA

U.S. launch of Innohep as DVT therapy announced at San Francisco meeting

Combination represents new strategy for treatment-resistant schizophrenia

First oral chemotherapy for colorectal cancer recommended for approval in Europe

Retinoid antagonists and their use described in recent patent by Roche

AHP's novel imide derivatives useful for serotonergic neuron-related conditions

New Y5 receptor antagonists claimed for eating disorders, etc. by Synaptic

NIH presents novel HIV-1 integrase inhibitors

Selective M3 receptor antagonists and their use described by Japanese scientists

U. of Mississippi prepares novel series of PPARgamma-activating agents

Recent patent covers Medicure's new pyridoxal analogues

Novel meiosis inhibitors emerge from Akzo Nobel R&D

Therapeutic products agreement finalized by Medarex and IDM

ZymoGenetics launched as independent biotechnology company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.